Does TADALAFIL Cause Therapy cessation? 159 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 159 reports of Therapy cessation have been filed in association with TADALAFIL (Esokalli Testosterone Booster Oral Dissolving Film). This represents 0.5% of all adverse event reports for TADALAFIL.
159
Reports of Therapy cessation with TADALAFIL
0.5%
of all TADALAFIL reports
1
Deaths
73
Hospitalizations
How Dangerous Is Therapy cessation From TADALAFIL?
Of the 159 reports, 1 (0.6%) resulted in death, 73 (45.9%) required hospitalization, and 3 (1.9%) were considered life-threatening.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TADALAFIL. However, 159 reports have been filed with the FAERS database.
What Other Side Effects Does TADALAFIL Cause?
Headache (3,196)
Drug ineffective (2,943)
Dyspnoea (2,881)
Death (1,917)
Diarrhoea (1,667)
Dizziness (1,374)
Nausea (1,368)
Asthenia (1,230)
Fatigue (1,135)
Hypertension (1,044)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which TADALAFIL Alternatives Have Lower Therapy cessation Risk?
TADALAFIL vs TAFAMIDIS
TADALAFIL vs TAFAMIDIS MEGLUMINE
TADALAFIL vs TAFASITAMAB
TADALAFIL vs TAFASITAMAB-CXIX
TADALAFIL vs TAFINLAR